Louis Janeira, MD
Cardiovascular Disease · Indianapolis, INNPI 1487651329
Payments from drug & device makers
Across 346 payments — averaging $26.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$2K
- Pfizer$904
- Johnson & Johnson$742
- AstraZeneca$719
- Amgen$644
- Heartflow, Inc.$504
- plus $3K from 21 others
What the payments were for
- Speaking & faculty fees$2,10024%
- Food & beverage$6,73476%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 26 | $2,447 |
| Pfizer | 41 | $904 |
| Johnson & Johnson | 43 | $742 |
| AstraZeneca | 26 | $719 |
| Amgen | 36 | $644 |
| Heartflow, Inc. | 20 | $504 |
| Boston Scientific | 21 | $485 |
| H. Lundbeck A S | 1 | $450 |
| Novartis | 26 | $379 |
| Merck | 26 | $363 |
| Amarin Pharma, Inc. | 13 | $360 |
| Sanofi-aventis U.S. LLC | 21 | $339 |
| E.r. Squibb & Sons, L.L.C. | 9 | $200 |
| Abbott | 5 | $141 |
| Astellas Pharma US Inc | 1 | $111 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $105 |
| Novo Nordisk | 6 | $99 |
| Bayer | 5 | $78 |
| Baxter Healthcare | 1 | $53 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Lexicon Pharmaceuticals, Inc. | 2 | $33 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $31 |
| Kestra Medical Technology Services, Inc. | 1 | $31 |
| Lundbeck LLC | 2 | $30 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| Impulse Dynamics (USA) Inc. | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,334 in reported general payments places this provider in the 70th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 475 | $551,677 |
| EntrestoSacubitril/Valsartan | 179 | $227,665 |
| JardianceEmpagliflozin | 206 | $218,652 |
| Repatha SureclickEvolocumab | 129 | $147,570 |
| FarxigaDapagliflozin Propanediol | 120 | $117,352 |
| XareltoRivaroxaban | 75 | $94,380 |
| VascepaIcosapent Ethyl | 62 | $47,639 |
| VerquvoVericiguat | 38 | $36,213 |
| OzempicSemaglutide | 23 | $27,480 |
| MounjaroTirzepatide | 16 | $19,199 |
| Icosapent Ethyl | 27 | $10,561 |
| Metoprolol Succinate | 946 | $10,186 |
| Ezetimibe | 449 | $8,442 |
| Atorvastatin Calcium | 952 | $8,363 |
| Colchicine | 87 | $5,343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $904 | $551,677475 claims |
| NovartisEntresto | $379 | $227,665179 claims |
| Boehringer IngelheimJardiance | $2,447 | $218,652206 claims |
| AstraZenecaFarxiga | $719 | $117,352120 claims |
| Johnson & JohnsonXarelto | $742 | $94,38075 claims |
| MerckVerquvo | $363 | $36,21338 claims |
| Novo NordiskOzempic | $99 | $27,48023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Indianapolis
- Atul ChughIndianapolis$775K
- Noel DasguptaIndianapolis$744K
- Vijay RaoIndianapolis$706K
- Roopa RaoIndianapolis$481K
- Julie ClaryIndianapolis$475K
- James TrippiIndianapolis$449K
- John MillerIndianapolis$354K
- Richard KovacsIndianapolis$338K
- David KovacichIndianapolis$327K
- Jose Emanuel FinetIndianapolis$299K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.